1004-39-3

Usage

Uses

Used in Pharmaceutical Industry:
4,6-Diamino-2-mercaptopyrimidine is used as a pharmacological agent for its ability to inhibit platelet aggregation and induce coronary vasodilation. These properties make it a potential candidate for the development of drugs targeting cardiovascular diseases, where platelet aggregation and coronary vasodilation are critical factors in managing the condition.
Used in Research and Development:
In the field of research and development, 4,6-diamino-2-mercaptopyrimidine serves as a valuable compound for studying its various pharmacological activities and potential applications in drug discovery. Its unique chemical properties and interactions with other molecules make it an interesting subject for further investigation and experimentation.
Used in Chemical Synthesis:
Due to its chemical properties, 4,6-diamino-2-mercaptopyrimidine can be utilized as a building block or intermediate in the synthesis of other complex organic compounds. Its reactivity and functional groups make it a versatile component in the development of new molecules with specific applications in various industries, such as pharmaceuticals, agrochemicals, and materials science.

InChI:InChI=1S/C4H6N4S/c5-2-1-3(6)8-4(9)7-2/h1H,(H5,5,6,7,8,9)

Upstream product

• 65349-40-8 4,6-diamino-1-benzoylamino-1H-pyrimidine-2-thione 
• 17356-08-0 thiourea 
• 109-77-3 malononitrile 
• 65349-39-5 2-benzoylthio-4,6-diaminopyrimidine 
• 141-52-6 sodium ethanolate 

Downstream Products

• 23994-93-6 2-(ethylthio)pyrimidine-4,6-diamine 
• 101423-64-7 5-(4-chloro-phenylazo)-2-(4-chloro-phenylsulfanyl)-pyrimidine-4,6-diyldiamine 
• 6638-40-0 (4,6-diamino-pyrimidin-2-ylmercapto)-acetic acid 
• 1005-39-6 4,6-diamino-2-methylthiopyrimidine 
• 1123-54-2 1H-1,2,3-triazolo[4,5-d]pyrimidin-7-amine 
• 40070-06-2 4,6-diaminopyrimidine-2-sulfinic acid 
• 110153-00-9 3,7-diamino-2-phenyl-thiazolo[3,2-a]pyrimidin-5-ylideneamine 
• 69466-02-0 N-(6-Amino-2-thioxo-1,2-dihydro-pyrimidin-4-yl)-benzamide 
• 65349-39-5 2-benzoylthio-4,6-diaminopyrimidine 
• 65349-40-8 4,6-diamino-1-benzoylamino-1H-pyrimidine-2-thione 
• 76664-37-4 4-Methoxy-thiobenzoic acid S-(4,6-diamino-pyrimidin-2-yl) ester 
• 84890-62-0 2-(benzylthio)pyrimidine-4,6-diamine 
• 412919-37-0 2-(phenylethylthio)pyrimidine-4,6-diamine 
• 1268273-27-3 2-((2-(bis(4-methoxybenzyl)amino)-4,6-diethoxypyrimidin-5-yl)thio)pyrimidine-4,6-diamine 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of 4-aminopyrimidine or 4,6-diaminopyrimidine derivatives as beta amyloid cleaving enzyme-1 inhibitors

A series of novel aminopyrimidine and diaminopyrimidine derivatives were designed and optimized to improve their potency and permeability relative to lead compound 1 (IC50?=?37.4?μM), which was discovered in a previous virtual screening. The po

Docking studies and development of novel 5-heteroarylamino-2,4-diamino-8-chloropyrimido-[4,5-b]quinolines as potential antimalarials

MOE-Dock (Docking software) was used to predict the binding modes of 10 novel and potent 5-substituted amino-2,4-diamino-8-chloropyrimido-[4,5-b]quinolines (compounds I-X) as part of our antimalarial drug development programme. This was done by analyzing the interaction of these compounds with the active sites of 11 enzymes present in Plasmodium falciparum and based on this, effective binding was observed to enzyme P. falciparum glutathione reductase (PfGR). The binding scores for compounds I-X with PfGR were also congruent with their antimalarial activity. Three additional analogs were then designed and synthesized based on the above docking study and the pharmacophoric requirements for this class.

2-[(3,3,3-trifluoropropyl)thio]-6-amino-9H-purine and preparation method thereof

The invention discloses 2-[(3,3,3-trifluoropropyl)thio]-6-amino-9H-purine and a preparation method thereof. 2-[(3,3,3-trifluoropropyl)thio]-6-amino-9H-purine can be used for preparation of 6-N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]adenosine

Preparation method for 6-N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]adenosine

The invention discloses a preparation method for 6-N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]adenosine. The preparation method comprises the following steps: subjecting a compound as shown in a formula (8) to glycosylation so as to obtain a c

Method for synthesis of adenine (by machine translation)

The invention discloses a synthetic method for adenine. Malononitrile and thiourea are employed as raw materials. The raw materials are subjected to a cyclization reaction under action of sodium alkoxide, and 4,6-diamino-2-sulfydryl pyrimidine. Then through three reaction routes, adenine is obtained. Though the method has many reaction steps, no refining or drying are needed for the product of each reaction step, the product can be used in the next reaction step, and the operation is simple. The raw materials are easily available, the prices are relatively low, the reaction conditions are mild, the operation is simple, the reaction steps are decreased, the reaction time is shortened, the overall reaction yield is high, and the synthetic method is suitable for industrial production.

Synthesis, dihydrofolate reductase inhibition, anti-proliferative testing, and saturation transfer difference1H-NMR study of some new 2-substituted-4,6-diaminopyrimidine derivatives

A series of 2-substituted-4,6-diaminipyrimidine derivatives were synthesized and evaluated for their dihydrofolate reductase (DHFR) inhibitory activity. Saturation transfer difference (STD) 1H-NMR experiments were used to probe the binding char

6-Amino-2-mercapto-3H-pyrimidin-4-one derivatives as new candidates for the antagonism at the P2Y12 receptors

P2Y12 plays an important role in platelet aggregation, which makes it an interesting target for antithrombotic agents. Compounds that antagonize P2Y12 include the active metabolites of thienopyridines and molecules that are structurally related to ATP, which is an antagonist of P2Y12. During the last few years, our group has been working on the development of P2Y12 receptors antagonists that are based on an extremely simple chemical structure, the 6-amino-2-mercapto-3H-pyrimidin-4-one, variously substituted at the sulfur and oxygen functions. This nucleus represents the simplified combination of two known P2Y12 antagonists: the active metabolite of the thienopyridines and ATP derivatives. The effects of the synthesized compounds were tested on ADP-induced human platelet aggregation, using light transmission aggregometry. None of the tested compounds induced platelet aggregation, while some of them, at concentration of 10-4 M, partially inhibited platelet aggregation induced by ADP 10-6 M. The most potent compound, 6b, antagonized the inhibitory effect of 2-methylthio-ADP on the forskolin-induced accumulation of cyclic-AMP in CHO FlpIN cells expressing recombinant human P2Y12-receptors. In addition, none of the tested compounds, including 6b, interfered with ligand binding to P1 receptors. Our results suggest that some of the synthesized compounds are specific antagonists of P2 receptors, and in particular of P2Y12 and suggest that further development of this structurally new series of compounds as P2Y12 receptors antagonists is recommended.

Microwave-expedited one-pot, two-component, solvent-free synthesis of functionalized pyrimidines

The synthesis of a series of diversely substituted pyrimidines under solvent-free conditions in good yields is described. Under microwave irradiation, a variety of nucleophilic substrates containing the N?C?N unit with ?-dicarbonyl compounds, ethyl cyanoacetate, malononitrile, and chalcones was cyclized to give pyrimidines. A combinatorial type approach for a one-step synthesis has been developed where a ring-closing condensation is followed by spontaneous aromatization to afford 28 functionalized and aryl/alkyl substituted pyrimidines. CSIRO 2007.

Synthesis and α1-adrenoceptor antagonistic activity of some 4-amino-5,7-dimethyl-2-(substituted) aminopyrido(2,3-d)pyrimidines

A series of new 4-amino-5,7-dimethyl-2-(substituted) aminopyrido(2,3-d)pyrimidines (5) have been synthesized and tested for selective α1-adrenoreceptor antagonistic activity. Some of the compounds were found to antagonize α1-adrenoreceptor in a competitive and reversible manner. When screened on rat anococcygeus muscle some of the compounds exhibited significant α1-adrenoreceptor antagonistic activity (pA2 values in the range of 5.2-7.8). The most potent compound (5j) was evaluated by an in vivo method and was found to reduce the systolic and diastolic blood pressure of spontaneously hypertensive rats. The percentage reduction in blood pressure by test compound 5j was found to be higher than that of the standard drug prazosin (CAS 19216-56-9) at the same dose level (1mg/kg p.o.). Chemically, prazosin is a 4-aminoquinazolin derivative. Pyridopyrimidine is a known bioisostere of quinazoline. The study revealed that isosteric replacement of the benzene ring of prazosin by a pyridine ring increases the potency.

INVESTIGATIONS IN THE SERIES OF HETEROCYCLES. L. CHARACTERISTICS OF THE REACTION OF MALONITRILE WITH ETHYL ALCOHOL IN THE PRESENCE OF SODIUM ETHOXIDE

In absolute alcohol in the presence of sodium ethoxide malonitrile is converted into ethyl cyanoethanimidate.The degree of conversion depends on the ratio of the initial concentrations of sodium ethoxide and malonitrile.The formation of the imidate is exo